Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and delivering medicines for people living with serious neurological and psychiatric conditions. The company says it pursues novel therapeutic approaches and concentrates on areas where better treatment options can make a meaningful difference. Its work spans both the development of new treatments and the commercialization of approved medicines.

Axsome’s commercial portfolio includes AUVELITY, SUNOSI, and SYMBRAVO. The company describes AUVELITY as a treatment for major depressive disorder and agitation associated with dementia due to Alzheimer’s disease; SUNOSI addresses excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea; and SYMBRAVO is approved for acute migraine treatment in adults. Indications and availability are subject to applicable prescribing information and regulatory approvals.

Alongside its marketed medicines, Axsome maintains a neuroscience research and development pipeline. Its stated areas of interest include Alzheimer’s disease agitation, attention-deficit/hyperactivity disorder, binge eating disorder, depression, schizophrenia, smoking cessation, epilepsy, fibromyalgia, migraine, and sleep disorders. The company describes its approach as identifying critical gaps in care and developing differentiated products, including therapies with novel mechanisms of action. Product candidates under investigation are not approved medicines.

The company’s activities encompass research and development, clinical studies, regulatory work, and commercial operations. Axsome’s website presents clinical trials as a way to translate scientific discoveries into potential treatment options, and invites eligible participants to learn about ongoing studies. The company also provides information and resources for patients, caregivers, healthcare professionals, and investors through its corporate website.

Axsome Therapeutics was incorporated in Delaware in January 2012 and is headquartered at One World Trade Center in New York City. Its corporate filings describe its business as the development and commercialization of innovative medicines for central nervous system conditions. Its current public identity emphasizes brain health and advancing treatment options for people affected by serious disorders.

The company states that its mission is to address some of the brain’s biggest problems so patients and their loved ones can flourish. Its careers materials describe a collaborative, entrepreneurial team committed to improving the lives of people with serious brain disorders. Axsome’s stated focus on unmet treatment needs connects its research, clinical programs, and commercial portfolio to its broader aim of improving patient outcomes.